EBRO 2017

ACT IV: Phase 3

• 745 pts • HR = 0.99

• “the rindopepimut combination showed OS data similar to expectations in the phase III study while patients in the control arm significantly outperformed.”

• Reanalysis of EORTC trial patient who met enrolment criteria showed this better analysis • RCTs are not perfect…. But better than this